282
Participants
Start Date
December 7, 2020
Primary Completion Date
October 31, 2022
Study Completion Date
April 28, 2023
ricolinostat
120 mg per dose in 12 mL liquid formulation
Placebo
12 mL liquid formulation placebo
NY Scientific, Brooklyn
The Center for Clinical Research, Winston-Salem
Triad Clinical Trials, Greensboro
Coastal Carolina Research Center, North Charleston
Palmetto Clinical Research, Summerville
Physicians Research Associates, LLC, Lawrenceville
Progressive Medical Research, Port Orange
DeLand Clinical Research Unit, Lake Mary
ClinCloud LLC, Maitland
APF Research LLC, Miami
International Research Associates LLC, Miami
Metabolic Research Institute Inc, West Palm Beach
Meridien Research, Tampa
Innovative Research of West Florida Inc, Clearwater
Sensible Healthcare LLC, Ocoee
Pinnacle Research Group LLC, Anniston
Olive Branch Family Medical Center, Olive Branch
MediSphere Medical Research Center, LLC, Evansville
Tandem Clinical Research, Marrero
Nerve and Muscle Center of Texas, Houston
Sun Research Institute, San Antonio
Diabetes & Glandular Disease Clinic, P.A., San Antonio
FutureSearch Trials of Neurology, Austin
Rocky Mountain Clinical Research, Idaho Falls
Wasatch Clinical Research LLC, Salt Lake City
Arizona Research Center, Phoenix
Advanced Biomedical Research of America, Las Vegas
National Research Institute, Huntington Park
Torrance Clinical Research Institute Inc, Lomita
Providence Clinical Research, North Hollywood
Altman Clinical and Translational Research Institute, La Jolla
Diabetes/Lipid Management & Research Center, Huntington Beach
Center for Clinical Research Inc, San Francisco
Diablo Clinical Research Inc, Walnut Creek
Hassman Research Institute, Berlin
Regenacy Pharmaceuticals LLC
INDUSTRY